CALGB Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer Adult CIRB - Late Phase Emphasis Closed to Accrual. Pts Have Completed Intervention Available to Open